Pfizer Reaffirms $59.5–62.5B 2026 Guidance, Targets Up to $3.00 EPS
PFE•Pfizer reaffirmed its 2026 guidance, expecting $59.5–$62.5 billion in revenue and $2.80–$3.00 EPS while emphasizing cost-cutting and onshoring to mitigate patent expirations. Management highlighted a robust oncology and obesity pipeline as drivers for growth and margin expansion through 2027.
1. 2026 Guidance Reaffirmation
Pfizer confirmed its full-year 2026 revenue forecast of $59.5–$62.5 billion and EPS guidance of $2.80–$3.00, maintaining its previous outlook despite looming patent expirations on key products.
2. Oncology and Obesity Pipeline Growth
The company emphasized continued investment in its oncology portfolio, including late-stage candidates, and the expansion of its obesity drug pipeline, projecting these platforms to drive incremental revenue through 2027.
3. Onshoring Production
Pfizer is relocating high-margin production to domestic facilities, aiming to reduce supply chain risks and benefit from favorable national drug pricing policies by aligning manufacturing with government priorities.
4. Cost-Cutting Measures and Margin Expansion
Aggressive cost-reduction initiatives, including operational efficiencies and workforce optimization, are designed to offset loss of exclusivity headwinds, targeting expanded operating margins in 2026 and beyond.
